MyoKardia, Inc.

( )
MYOK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
CTLTCatalent, Inc. 0.05%85.232.1%$238.82m
SAVACassava Sciences, Inc. 0.00%11.410.0%$211.33m
HZNPHorizon Therapeutics Plc 0.00%78.165.8%$169.44m
JAZZJazz Pharmaceuticals Plc 0.00%139.742.4%$164.59m
MRNSMarinus Pharmaceuticals, Inc. 7.57%12.507.8%$137.01m
CORTCorcept Therapeutics, Inc. 0.00%17.555.5%$123.89m
VRXValeant Pharmaceuticals International, Inc. 0.00%14.8814.1%$87.56m
MYOKMyoKardia, Inc. 0.00%134.131.8%$62.22m
BHCBausch Health Cos., Inc. 0.00%14.880.0%$60.52m
AMRNAmarin Corp. Plc -0.99%4.001.5%$57.91m
ARGXargenx SE 0.00%260.200.0%$55.65m
SAGESAGE Therapeutics, Inc. 0.00%59.678.6%$44.13m
GWPHGW Pharmaceuticals Plc 0.00%97.826.2%$39.39m
AXSMAxsome Therapeutics, Inc. 0.00%72.281.9%$38.96m
PRGOPerrigo Co. Plc 0.00%45.676.8%$36.77m

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.